| Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes KM Kortüm, EK Mai, NH Hanafiah, CX Shi, YX Zhu, L Bruins, S Barrio, ... Blood 128 (9), 1226-1233, 2016 | 234 | 2016 |
| Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation X Jing, P Nicole, E Volker, EK Mai, NH Md Hanafiah, N Lehners, R Penzel, ... Oncogenesis 6, e337, 2017 | 86 | 2017 |
| Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition MS Raab, N Lehners, J Xu, AD Ho, P Schirmacher, H Goldschmidt, ... Blood, The Journal of the American Society of Hematology 127 (17), 2155-2157, 2016 | 61 | 2016 |
| Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures. D Yu, C Jin, M Ramachandran, J Xu, B Nilsson, O Korsgren, KB Le, ... PLoS One 8 (1), e54952-e54952, 2013 | 50 | 2013 |
| Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities N Giesen, N Paramasivam, UH Toprak, D Huebschmann, J Xu, S Uhrig, ... Haematologica, 2022 | 17 | 2022 |
| Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders N Lehners, E Ellert, J Xu, J Hillengass, J Leichsenring, A Stenzinger, ... Leukemia & lymphoma 59 (11), 2660-2669, 2018 | 6 | 2018 |
| Profiling of Oncogenic Signaling in Multiple Myeloma—Association with Biology, Disease Progression and Prognosis N Lehners, J Xu, T Hielscher, L Rasche, E Ellert, A Stenzinger, ... Blood 132, 3206, 2018 | 2 | 2018 |
| Comprehensive genomic characterization of refractory multiple myeloma reveals a complex mutational and structural landscape associated with drug resistance N Lehners, UH Toprak, J Xu, N Paramasivam, D Hübschmann, M Fröhlich, ... Blood 130, 266, 2017 | 1 | 2017 |
| Signaling Pathway Profiling in Multiple Myeloma MS Raab, J Xu, T Hielscher, N Lehners, E Ellert, AD Ho, P Schirmacher, ... Blood 124 (21), 644, 2014 | 1 | 2014 |
| Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: A prospective cohort study JP Yaqi Li, Jing Xu, Xiang Hu, Yikuan Chen, Fangqi Liu, Yun Chen, Xiaoji Ma ... International Journal of Surgery, 2024 | | 2024 |
| Effect of dynamic circulating tumor DNA minimal residual disease detection on recurrence surveillance and second resection rate after curative intent resection of colorectal … JP Yaqi Li, Jing Xu, Yikuan Chen, Xiaoji Ma, Xiang Hu, Yun Chen, Lei Sun ... ASCO-GI 41 (4_suppl), 242, 2023 | | 2023 |
| A Comprehensive Analysis of Single-Cell Chromatin Accessibility and Gene Expression Identifies Intra-Tumor Heterogeneity and Molecular Treatment Responses in Relapsed … AM Poos, JP Mallm, SM Tirier, N Casiraghi, H Susak, N Giesen, K Bauer, ... Blood 134, 575, 2019 | | 2019 |
| Biallelic Inactivation of Multiple Tumor Suppressors Is Associated with Early Relapse after Stem Cell Transplant in Newly Diagnosed Myeloma N Weinhold, J Xu, M Fröhlich, AM Poos, L John, C Müller-Tidow, S Sauer, ... Blood 134, 1783, 2019 | | 2019 |
| Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma SM Tirier, JP Mallm, N Casiraghi, H Susak, N Giesen, AM Poos, K Bauer, ... Blood 134, 571, 2019 | | 2019 |
| The mutational landscape underlying carfilzomib and pomalidomide resistance in relapsed/refractory multiple myeloma J Xu, N Giesen, N Paramasivam, H Goldschmidt, B Brors, MS Raab, ... Clinical Lymphoma Myeloma and Leukemia 19 (10), e83-e84, 2019 | | 2019 |
| Oncogene-induced senescence N Giesen, E Ellert, J Xu, J Hillengaß, J Leichsenring, A Stenzinger, ... | | 2018 |
| Oncogene Induced Senescence As a Potential Breakpoint Mechanism Against Malignant Transformation in Plasma Cell Disorders N Lehners, E Ellert, J Xu, H Goldschmidt, M Andrulis, MS Raab Blood 128 (22), 4474, 2016 | | 2016 |
| Molecular signaling in multiple myeloma: association of RAS/RAF mutation status and MAPK pathway activation in primary myeloma patient biopsies J Xu, N Pfarr, V Endris, EK Mai, NHM Hanafiah, N Lehners, R Penzel, ... Cancer Research 76, 2016 | | 2016 |
| Targeted Sequencing of Relapsed/Refractory Myeloma Patients Identifies an Enrichment of Mutations in Cereblon and MAPK Pathways EK Mai, KM Kortuem, N Hanafiah, S Barrio, LA Bruins, M Merz, J Xu, ... Blood 126 (23), 723, 2015 | | 2015 |
| Signaling pathway profiling in multiple myeloma J Xu, T Hielscher, N Lehners, E Ellert, AD Ho, P Schirmacher, ... AACR 75 (15 Supplment), 2423-2423, 2015 | | 2015 |
